ENSC · Ensysce Biosciences, Inc.
$0.39
0.00 (-1.17%)
At close · Sep 1
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company's ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.45M
Shares
19.46M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2020-12-31 | $184,776,163 | 10-K/A, filed 2021-06-08 |
| 2019-12-31 | $11,583,473 | 10-K/A, filed 2021-06-08 |
Key facts
CIK
1716947
CUSIP
293602504
13F (30d)
17 filings
17 filers
Visit website
Investor relations